Avalo Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $249 | $0 | $0 | $571 |
Gross Profit | 963 | -343 | 46 | 792 |
EBITDA | -12,827 | -9,439 | -5,195 | -8,355 |
EBIT | -12,861 | -9,472 | -5,238 | -8,398 |
Net Income | 23,037 | 98,463 | -121,290 | -8,167 |
Net Change In Cash | 249 | 0 | 0 | 571 |
Free Cash Flow | -11,527 | -16,283 | -6,202 | -2,924 |
Cash | 81,858 | 93,426 | 110,181 | 7,416 |
Basic Shares | 10,784 | 7,653 | 859 | 801 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $1,924 | $18,051 | $5,398 | $6,699 |
Gross Profit | 640 | 14,617 | 3,907 | 6,399 |
EBITDA | -27,955 | -37,294 | -80,497 | -45,451 |
EBIT | -28,113 | -37,460 | -82,154 | -47,294 |
Net Income | -31,544 | -41,658 | -84,349 | -64,384 |
Net Change In Cash | 1,924 | 18,051 | 5,398 | 6,699 |
Cost of Revenue | 15,377 | |||
Free Cash Flow | -30,838 | -26,846 | -71,005 | -40,602 |
Cash | 7,415 | 13,172 | 54,585 | 18,919 |
Basic Shares | 277 | 39 | 36 | 25 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$1.25 |
2024-06-30 | -$14.07 |
2024-03-31 | -$141 |
2023-12-31 | -$116.21 |
